Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A consolidated Locations section listing all participating states has been added, and the previous per-state location entries were removed. The page shows Revision: v3.3.3.
    Difference
    1%
    Check dated 2025-12-24T21:38:38.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    New data added: EU CTIS number 2024-512005-87-00 and study completion date 2026-05-01, plus updated last update indicators (2025-11-28, 2025-11). Some older timestamps and the 'Last Update Posted' entry were removed.
    Difference
    0.1%
    Check dated 2025-12-16T15:53:07.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The Publications section is now automatically filled from PubMed and may not relate to the study; the page revision is now v3.3.2 (up from v3.2.0).
    Difference
    0.0%
    Check dated 2025-11-25T10:10:26.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    - Removed the government funding status notice banner. Study details, eligibility criteria, and other trial information remain unchanged.
    Difference
    0.1%
    Check dated 2025-11-18T03:27:21.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Added the location 'Tainan, Taiwan' to the study locations and removed 'Tainan City, Taiwan'. This updates how sites in Taiwan are identified and located for potential participants.
    Difference
    0.0%
    Check dated 2025-11-10T22:07:26.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The new screenshot shows only minor layout and formatting updates on the Study Details page, with no substantive changes to eligibility criteria, endpoints, or the list of study locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T19:00:14.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.